文献速递神经肿瘤

恶性脑肿瘤放射增敏剂的研究现状与未来展望:系统综述

Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review.
PubMed 文献 · World Neurosurg · 2021-05-08

该系统综述遵循PRISMA指南检索多个数据库,纳入报告非抗肿瘤放射增敏剂联合放疗治疗恶性中枢神经系统肿瘤临床证据的文章。共识别22种放射增敏剂,仅2种分别改善胶质母细胞瘤和脑转移患者的总生存期,部分药物改善无进展生存期,但毒性反应导致9种药物调整方案或停用。

要点

  • 22种放射增敏剂中仅2种显示有限生存获益
  • 部分药物改善无进展生存期但毒性谱广
  • 9种药物因毒性需调整方案或停用

核心结论

  • 恶性中枢神经系统肿瘤放射增敏剂进展有限,仅2种显示有限生存改善。
  • 可能需要基于不依赖血脑屏障穿透机制的合成药物设计等替代策略。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索PubMed、EMBASE、Cochrane和Web of Science数据库。
  • 纳入报告非抗肿瘤放射增敏剂联合放疗治疗恶性中枢神经系统肿瘤临床证据的文章。
  • 关注数据包括推测作用机制、中位总生存期、无进展生存期和不良事件。

主要发现

  • 共识别22种独特的放射增敏剂。
  • 仅2/22种药物(fluosol联合氧气和efaproxiral)分别改善胶质母细胞瘤和脑转移患者的总生存期。
  • 一项更大规模研究未能证实efaproxiral的生存获益。
  • 使用甲硝唑、甘氨双唑钠和氯喹报告了无进展生存期改善。
  • 毒性反应范围广泛,导致9种药物调整方案或完全停用。

关键数值与推荐

  • 2/22种放射增敏剂显示总生存期改善,分别针对胶质母细胞瘤和脑转移。
  • 甲硝唑、甘氨双唑钠和氯喹报告无进展生存期改善。
  • 9种药物因毒性需调整方案或停用。

临床怎么用

  • 目前放射增敏剂临床选择有限,需权衡生存获益与毒性风险。
  • 考虑使用甲硝唑、甘氨双唑钠或氯喹改善无进展生存期时需监测毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy (RT) is the cornerstone of management of malignant brain tumors, but its efficacy is limited in hypoxic tumors. Although numerous radiosensitizer compounds have been developed to enhance the effect of RT, progress has been stagnant. Through this systematic review, we provide an overview of radiosensitizers developed for malignant brain tumors, summarize their safety and efficacy, and evaluate areas for possible improvement. METHODS: Following PRISMA guidelines, PubMed, EMBASE, Cochrane, and Web of Science were searched using terminology pertaining to radiosensitizers for brain tumor RT. Articles reporting clinical evidence of nonantineoplastic radiosensitizers with RT for malignant central nervous system tumors were included. Data of interest were presumed mechanism of action, median overall survival (OS), progression-free survival (PFS), and adverse events. RESULTS: Twenty-two unique radiosensitizers were identified. Only 2/22 agents (fluosol with oxygen, and efaproxiral) showed improvement in OS in patients with glioblastoma and brain metastasis, respectively. A larger study was not able to confirm the latter. Improved PFS was reported with use of metronidazole, sodium glycididazole, and chloroquine. There was a wide range of toxicities, which prompted change of schedule or complete discontinuation of 9 agents. CONCLUSIONS: Progress in radiosensitizers for malignant CNS tumors has been limited. Only 2 radiosensitizers have shown limited improvement in survival. Alternative strategies such as synthetic drug design, based on a mechanism of action that is independent of crossing the blood-brain barrier, may be necessary. Use of drug development strategies using new technologies to overcome past challenges is necessary.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Beg U, Snyder BM, Madhani SI, et al. Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review. World Neurosurg. 2021. PMID: 33974987. doi:10.1016/j.wneu.2021.04.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。